Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H12O6 |
Molecular Weight | 336.295 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(CC2=C(O)C3=CC=CC=C3OC2=O)C(=O)OC4=CC=CC=C14
InChI
InChIKey=DOBMPNYZJYQDGZ-UHFFFAOYSA-N
InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2
Molecular Formula | C19H12O6 |
Molecular Weight | 336.295 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB00266Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728
Sources: https://www.drugbank.ca/drugs/DB00266
Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728
Dicumarol is an coumarin-like compound found in sweet clover. It is used as oral anticoagulant and acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (prothrombin and factors VII, IX, and X). It results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. Dicumarol is also used in biochemical experiments as an inhibitor of reductases.
Originator
Sources: http://www.jbc.org/content/138/1/21.full.pdf
Curator's Comment: Campbell, H.A. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry, 138, 21–33.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1930 Sources: https://www.drugbank.ca/drugs/DB00266 |
2.0 µM [IC50] | ||
Target ID: CHEMBL3623 Sources: https://www.drugbank.ca/drugs/DB00266 |
10.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugbank.ca/drugs/DB00266 |
Preventing | DICUMAROL Approved UseFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis. Launch Date1944 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
521 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.84 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.03% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 59.8+15.3 years n = 71 Health Status: unhealthy Age Group: 59.8+15.3 years Sex: M+F Population Size: 71 Sources: |
|
2100 mg single, oral Overdose |
unknown n = 1 |
Disc. AE: Distended blood vessels... AEs leading to discontinuation/dose reduction: Distended blood vessels (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Distended blood vessels | 1 patient Disc. AE |
2100 mg single, oral Overdose |
unknown n = 1 |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. | 1996 May 10 |
|
Coumarin-based inhibitors of HIV integrase. | 1997 Jan 17 |
|
Fulminant hepatic failure associated with dicoumarol therapy. | 1998 Feb |
|
NRH:quinone oxidoreductase2 (NQO2). | 2000 Dec 1 |
|
Coumarin derivatives and breast-feeding. | 2000 Jun |
|
Phosphorylation is involved in the activation of metal-regulatory transcription factor 1 in response to metal ions. | 2001 Nov 9 |
|
P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. | 2003 Dec 9 |
|
Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol. | 2003 Mar 15 |
|
Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. | 2005 Apr 1 |
|
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. | 2005 Feb |
|
Dicoumarol relieves serum withdrawal-induced G0/1 blockade in HL-60 cells through a superoxide-dependent mechanism. | 2005 Jun 1 |
|
Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression. | 2006 Aug 1 |
|
Molecular cloning of a novel type of rat cytoplasmic 17beta-hydroxysteroid dehydrogenase distinct from the type 5 isozyme. | 2006 Jun |
|
Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target. | 2007 Dec |
|
The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells. | 2009 Jul 15 |
|
Analysis of couch position tolerance limits to detect mistakes in patient setup. | 2009 Oct 29 |
|
Protective effect of sulforaphane against cisplatin-induced mitochondrial alterations and impairment in the activity of NAD(P)H: quinone oxidoreductase 1 and γ glutamyl cysteine ligase: studies in mitochondria isolated from rat kidney and in LLC-PK1 cells. | 2010 Nov 10 |
|
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. | 2010 Oct 6 |
|
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists. | 2011 Oct 27 |
|
NAD(P)H:quinone oxidoreductase 1 is induced by progesterone in cardiomyocytes. | 2012 Jun |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2113031
Dicoumarol inhibits rat liver microsomal vitamin K epoxide reductase with IC50=2 uM and cytosolic DT-diaphorase with IC50=0.05 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:06:24 GMT 2023
by
admin
on
Fri Dec 15 15:06:24 GMT 2023
|
Record UNII |
7QID3E7BG7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C45597
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
||
|
WHO-VATC |
QB01AA01
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
||
|
WHO-ATC |
B01AA01
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07101MIG
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
DB00266
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
17860
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
3223
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
DICOUMAROL
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
4513
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
DICUMAROL
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | Description: A white or creamy white, crystalline powder; odour, characteristic, faint.Solubility: Practically insoluble in water, ethanol (~750 g/l) TS and ether R.Category: Anticoagulant.Storage: Dicoumarol should be kept in a well-closed container, protected from light.Definition: Dicoumarol contains not less than 98.5% and not more than 101.0% of C19H12O6, calculated with reference to the dried substance. | ||
|
7QID3E7BG7
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
D001728
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
221570
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
54676038
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
100000082921
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
6808
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
dicoumarol
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
2897
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
200-632-9
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
1598
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1466
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
41834
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
C310
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
66-76-2
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
867
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
m4370
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID8021729
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |